An observational study in All Tumor Types, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Recruiting at 136 sites in 20 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Observational
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Patients are recruited in the platform for the research purpose of 5 downstream projects. For more information, please have a look at the "Groups and cohorts" section.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 4,975 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →European Organisation for Research and Treatment of Cancer - EORTC is the lead sponsor of 352 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with pathologically confirmed selected tumor types.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary
Genetic: RP-1828 IMMUcan
The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS
Genetic: RP-1759 AYA/TYA
This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population. Tumor types: all 10 EURACAN domains
Genetic: RP-1843 Arcagen
The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon). Tumor type: Thorax
Genetic: RP-1920 BioRadon
The main objective of the 2148 Minimal Residual Disease Assessment project is to assess the potential of circulating tumor DNA (ctDNA) as a surrogate marker of recurrence by studying its positive predictive value (PPV). This will help determine how accurately ctDNA can predict cancer recurrence. Tumour types: Head and Neck, Melanoma
Genetic: 2148 MRD
WES, lcWGS and RNAseq, multiplex IF and IMC
WES, RNAseq and EPIC array
NGS panel
NGS panel
ctDNA detection and WES
To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care
material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Time frame: 5 years
To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future;
Time frame: 5 years
To investigate the molecular pathways related to the development of specific tumors from a biological point of view;
Time frame: 5 years
To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally;
Time frame: 5 years
To collect large series of homogeneous clinical data to analyse the disease course and treatment performed;
Time frame: 5 years
To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers;
Time frame: 5 years
To perform biospecimen and data based high quality research aiming to facilitate the discovery of new test for tumor biomarkers or facilitate the establishment of validated tests for tumor biomarkers;
Time frame: 5 years
To identify patients with molecular alterations in their tumor that can be matched to biomarker-driven clinical trials, to facilitate enrollment of cancer patients in biomarker-driven clinical trials.
Time frame: 5 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 136 sites across 20 countries. Choose a country and city above to see the rest.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European Organisation for Research and Treatment of Cancer - EORTC →